BidaskClub Upgrades Genomic Health (GHDX) to “Hold”

Genomic Health (NASDAQ:GHDX) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Tuesday.

Several other analysts also recently weighed in on the stock. Canaccord Genuity reissued a “buy” rating and issued a $35.00 price target on shares of Genomic Health in a research note on Wednesday, September 27th. ValuEngine raised shares of Genomic Health from a “sell” rating to a “hold” rating in a research note on Friday. Jefferies Group reissued a “hold” rating and issued a $33.00 price target on shares of Genomic Health in a research note on Thursday, September 14th. Cowen reissued a “hold” rating and issued a $34.00 price target on shares of Genomic Health in a research note on Friday, September 1st. Finally, Zacks Investment Research raised shares of Genomic Health from a “sell” rating to a “hold” rating in a research note on Friday, October 13th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $31.57.

Shares of Genomic Health (NASDAQ GHDX) opened at $36.94 on Tuesday. Genomic Health has a fifty-two week low of $26.37 and a fifty-two week high of $37.07.

In other Genomic Health news, insider Laura Leber sold 21,000 shares of the business’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $33.29, for a total value of $699,090.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Kimberly J. Popovits sold 20,000 shares of the business’s stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $31.50, for a total transaction of $630,000.00. The disclosure for this sale can be found here. Insiders sold 57,379 shares of company stock valued at $1,840,621 over the last three months. 46.20% of the stock is currently owned by insiders.

Hedge funds have recently added to or reduced their stakes in the business. Cubist Systematic Strategies LLC purchased a new position in shares of Genomic Health in the third quarter valued at about $138,000. SG Americas Securities LLC increased its position in shares of Genomic Health by 37.8% in the second quarter. SG Americas Securities LLC now owns 6,122 shares of the medical research company’s stock valued at $199,000 after acquiring an additional 1,679 shares during the period. Legal & General Group Plc increased its position in shares of Genomic Health by 11.4% in the second quarter. Legal & General Group Plc now owns 6,932 shares of the medical research company’s stock valued at $226,000 after acquiring an additional 710 shares during the period. Jane Street Group LLC purchased a new position in shares of Genomic Health in the third quarter valued at about $227,000. Finally, Parametric Portfolio Associates LLC increased its position in shares of Genomic Health by 5.8% in the second quarter. Parametric Portfolio Associates LLC now owns 8,051 shares of the medical research company’s stock valued at $262,000 after acquiring an additional 441 shares during the period. Hedge funds and other institutional investors own 89.61% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://sportsperspectives.com/2017/12/19/bidaskclub-upgrades-genomic-health-ghdx-to-hold.html.

About Genomic Health

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Analyst Recommendations for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply